Fabio Pammolli Summarizes Research on Pharma R&D

According to Pammoli, screening has improved (attrition rates decreasing in all phases of clinicaltrials) and focus has shifted to oncology, rare diseases and advanced therapies. Find out more here.

You might also be interested in:

Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
PRMA Consulting Announces New Singapore Office and Virtual Open House 08/11/2020
How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
Syapse and FDA Leverage Real-World Data to Study Impact of… 10/05/2020
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
Are Healthcare Prices in the U.S. Too High, Too Low, or Both? 08/25/2020
BHE Rebrands Itself as Panalgo In Effort To Empower Pharma,… 08/14/2020